PSMA/CD3 TRI-SPECIFIC T-CELL ACTIVATING CONSTRUCT HPN424
Advanced Prostate Cancer
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)protein_peptidePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
514 Active assets in the Advanced Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avodart Bay State Clinical Trials, Inc. | Phase 4 | BBB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
Degarelix Bayer | Phase 4 | BBB |
PROPOFOL Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
AVOLVE Masonic Cancer Center, University of Minnesota | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →